Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 8/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | NPY4R | P50391 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21297140 | 1.00 | FAP (0.35) | FAPMGLLFURINSIRT2C3AR1 | |
| SCHEMBL21297079 | 1.00 | FAP (0.35) | FAPMGLLFURINSIRT2C3AR1 | |
| SCHEMBL21297142 | 1.00 | FAP (0.35) | FAPMGLLFURINSIRT2C3AR1 | |
| SCHEMBL15870228 | 0.93 | FAP (0.34) | FAPFURINSIRT2HRH1NPY1R | |
| SCHEMBL31294572 | 0.93 | MGLL (0.36) | FAPMGLLFURINC3AR1HRH1 | |
| SCHEMBL30781655 | 0.93 | MGLL (0.36) | FAPMGLLFURINC3AR1HRH1 | |
| SCHEMBL31045369 | 0.93 | MGLL (0.36) | FAPMGLLFURINC3AR1HRH1 | |
| SCHEMBL30781641 | 0.93 | MGLL (0.36) | FAPMGLLFURINC3AR1HRH1 | |
| SCHEMBL16870158 | 0.92 | C3AR1 (0.41) | FAPMGLLFURINC3AR1 | |
| SCHEMBL22133461 | 0.92 | FURIN (0.34) | FAPMGLLFURINC3AR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | FAP 363/4885MGLL 1851/4885FURIN 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.